NYSE:PFE
Pfizer Inc (PFE)
25.71
+0.37 (1.46%)
as of Jun 4, 2026, 6:38:50 pm Market Open.
579 watching
Financials 
Technical Analysis 0
Investor Insights
Jun 4, 2026, 12:00 amThis summary was created by AI, based on 31 opinions in the last 12 months.
Pfizer Inc (PFE) is facing significant challenges stemming from a patent cliff, leading to concerns about its drug pipeline and growth prospects in the coming years. Analysts emphasize the company's attractive dividend yield, which hovers around 6-7%, making it appealing for income-focused investors. However, many reviews suggest that the lack of earnings momentum and the need for new blockbuster drugs remain critical issues. Despite a robust pipeline and recent acquisitions, the absence of immediate catalysts for growth has left investors cautious. Overall, while Pfizer provides a decent dividend, its future performance hinges on successful drug development and navigating market sentiment around healthcare reforms.
Consensus
Hold
Valuation
Undervalued
Similar
NVO
BUY
It has always been part of their health care portfolio. It is losing some lustre and interest created by Covid but is still a good health care company with a good dividend. He likes others as well, maybe a bit better.
Robert LauzonOwned
biotechnologypharmaceutical
HOLD
When you're looking at pharma companies, you want to see the breadth of drugs that are in the pipeline, and any blockbuster drugs in there. You're also looking for dividends. Yield is 3.4%.
Stan WongOwned
biotechnologypharmaceutical
BUY
PFE vs. JNJ Coin flip. Both are stable for the long run. PFE is slightly cheaper right now.
Jason MannOwned
biotechnologypharmaceutical
SELL
Always a wall of worry around drug pricing, but rarely does it have a large impact. He sold this name after record revenues from vaccine news. He likes AZN, which is getting approval after approval. Another one is LLY, focusing on its diabetes and weight loss drug.
Jamie Murray No
biotechnologypharmaceutical
DON'T BUY
The entire drug sector hasn't been investable since the 1990s, because governments control drug prices and patent expiries. Pfizer is struggling to replace drugs coming off patent, like their cholesterol drug. It's really tough. It's a defensive sector, so the drug companies will hold up better and offer dividend growth.
biotechnologypharmaceutical
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
Premium contentPAST TOP PICK
PAST TOP PICK
(A Top Pick May 28/20, Up 45%) A defensive. Back then, they were working on the vaccine and luckily theirs was the most effective. He trimmed at $55, but still likes and holds it. The company has in the past struggled to build a pipeline of drugs. This morning they announced they will buy a company that treats migraines. They're spending $11 billion on their pipeline, which is promising. They earned $25 billion revenues in vaccines in 2021. Pays a great dividend. Remains a core holding.
biotechnologypharmaceutical
Premium contentTOP PICK
Stockchase Research Editor: Michael O'Reilly PFE has a long pipeline of new drugs focusing on oncology, rare diseases and vaccines, generating over $50 billion in annual sales. It trades at 13x earnings compared to peers at 20x. Latest reported earnings beat expectations by 27% and supports a ROE over 34%. Its dividend is backed by a payout ratio under 40% of cashflow. It is managing its cash reserves conservatively, maintaining a good war chest, while still retiring debt. We would recommend a stop loss at $42.00, looking to achieve $60.50 -- upside potential of 19%. Yield 3.0% (Analysts’ price target is $60.47)
biotechnologypharmaceutical
DON'T BUY
Has done extremely well with Covid solutions. Not inexpensive for its growth rate. A concern for the stock, though not for humanity, is this opportunity will exhaust itself. Not a bad name if Covid will be a chronic situation. All pharma races the patent clock. He'd prefer MRK.
biotechnologypharmaceutical
HOLD
Value and price momentum score well. High ROE, 13x price to earnings. Healthy yield of 3%, very reasonable payout ratio. You can own it through the cycles.
Jason MannOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
